iZafe Group (IZAFE-B) Q4 2015 earnings summary

Executive summary

• 2015 consolidated loss after tax narrowed to SEK 2.60M from SEK 3.17M; year-end equity ratio rose to 70% from 60%.

• Development and commercialization centered on Medcheck medication-review software and Dosell, a home-care medication dispenser; partnership discussions and patent proceedings remained key milestones.

Financial highlights

• Consolidated loss before financial items was SEK 2.93M versus SEK 3.51M in 2014; loss after financial items was SEK 3.03M versus SEK 3.61M.

• Net loss after tax was SEK 2.60M versus SEK 3.17M; reported EPS was SEK -0.30 versus SEK -0.47.

• Consolidated total assets were SEK 12.42M at year-end, down from SEK 15.10M; cash and bank balances were SEK 109,745 versus SEK 270,437.

Outlook and guidance

• 2016 priorities included expected Dosell European patent progress and a hoped-for European patent decision for Medcheck.

• Discussions continued with a prospective large partner to develop a broader senior-focused home-safety offering incorporating Dosell.

• Medcheck’s appeal before the Patent Appeals Board was expected to be considered within one to two years; patent litigation was scheduled for a combined trial in March 2016.